Better Therapeutics, Inc. (BTTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
BTTX Stock Price Chart Interactive Chart >
BTTX Price/Volume Stats
| Current price | $2.03 | 52-week high | $29.40 |
| Prev. close | $2.27 | 52-week low | $0.91 |
| Day low | $1.94 | Volume | 4,820,200 |
| Day high | $2.48 | Avg. volume | 4,092,596 |
| 50-day MA | $1.80 | Dividend yield | N/A |
| 200-day MA | $5.73 | Market Cap | 47.92M |
Better Therapeutics, Inc. (BTTX) Company Bio
As of October 29, 2021, Mountain Crest Acquisition Corp. II was acquired by Better Therapeutics, Inc., in a reverse merger transaction. Mountain Crest Acquisition Corp. II. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or related business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.
Latest BTTX News From Around the Web
Below are the latest news stories about Better Therapeutics Inc that investors may wish to consider to help them evaluate BTTX as an investment opportunity.
Better Therapeutics to Participate in Two Upcoming Investor EventsSAN FRANCISCO, January 20, 2022--Better Therapeutics, Inc. ("Better Therapeutics"; NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing cognitive behavioral therapy to address root causes of cardiometabolic diseases, today announced that Kevin Appelbaum, Chief Executive Officer, is scheduled to participate in two upcoming investor events as follows: |
Use this app and call me in the morning: The promise of prescription digital therapeuticsWhen it comes to treating diseases, some doctors are looking beyond traditional medicines as therapies. A growing number of health care professionals are recognizing the value of prescription digital therapeutics (PDTs), a type of evidence-based software program that provides behavioral therapy or other type of therapeutic intervention. Digital therapeutics can... |
Better Therapeutics Highlights Recent Progress and Updates Outlook Through Q1 2022SAN FRANCISCO, January 06, 2022--Better Therapeutics, Inc. ("Better Therapeutics"; NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing cognitive behavioral therapy to address root causes of cardiometabolic diseases, today provided an update on recent progress. |
Better Therapeutics Appoints Deepti Sodhi Jaggi, PharmD, as Chief Strategy OfficerSAN FRANCISCO, November 30, 2021--Better Therapeutics, Inc. ("Better Therapeutics"; NASDAQ: BTTX), a prescription digital therapeutics company developing cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced the appointment of Deepti Sodhi Jaggi, PharmD, as its Chief Strategy Officer. |
Chardan Capital Thinks Mountain Crest Acquisition II’s Stock is Going to RecoverChardan Capital analyst Keay Nakae reiterated a Buy rating on Mountain Crest Acquisition II (BTTX – Research Report) today and set a price target of $17.00. The company's shares closed last Tuesday at $6.41, close to its 52-week low of $6.36. According to TipRanks.com, Nakae is a 5-star analyst with an average return of 18.8% and a 47.5% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Emergent Biosolutions, and Kaleido Biosciences. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Mountain Crest Acquisition II with a $17.00 average price target, representing a 145.7% upside. |
BTTX Price Returns
| 1-mo | 111.57% |
| 3-mo | -30.72% |
| 6-mo | -71.25% |
| 1-year | -79.66% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -56.34% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...